Investigation of new molecular target of neuroblastoma therapy: The role of p53 pathway in neuroblastoma cell death
神经母细胞瘤治疗新分子靶点研究:p53通路在神经母细胞瘤细胞死亡中的作用
基本信息
- 批准号:17591077
- 负责人:
- 金额:$ 2.11万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Neuroblastoma (NB) is the most common pediatric solid malignant tumor derived from the sympathetic nervous system. We investigated the inhibitor of p53-dependent cell death in NB cells. The candidate for the inhibitor, which was highly expressed in Doxorubicin-resistant cells and bound to p53 in nucleus, seemed to be p53-E3 ubiquitine ligase HDM2.Of note, both of p53 and HDM2 were accumulated in the Doxorubicin-resistant NB cells although HDM2 accelerates p53 degradation in a proteasome dependent manner. Recently, it has reported that overproduction of Mdm2, resulting from a naturally occurring SNP309, inhibits chromatin-bound p53 from activating the transcription of its target genes (JBC, Arva NC et al., 2005). These results prompted us to study the existence of SNP309 HDM2 in NB cells. However, we could detect the heterozygous SNP only in SK-N-SH (sensitive) but not in IMR32 (resistant), NB-19 (resistant) and NB-9 (sensitive) cells. Next, we sequenced the p53-binding domain of HDM2 t … More o verify the p53-HDM2 interaction in NB cells and could not found mutations in the p53 binding domain of HDM2We employed a panel of cell lines to determine whether the p53-dependent cell death in neuroblastoma (NB) cells is caused by apoptotic cellular function, and we further studied the molecular mechanism of apoptosis induced via the p53-dependent pathway. We obtained evidence that a type of p53-dependent stress, doxorubicin (Doxo) administration, causes accumulation of p53 in the nucleus of NB cells and phosphorylation of several serine residues in both Doxo-sensitive and-resistant cell lines. Up-regulation of p53-downstream molecules in cells and accumulation of Noxa in the mitochondrial fraction were observed only in Doxo-sensitive NB cells. Significance of Noxa in the Doxo-induced NB cell death was confirmed by Noxa-knockdown experiments. Mitochondrial dysfunction, including cytochrome c release and membrane potential dis-regulation, occurred and resulted in the activation of the intrinsic caspase pathway (Kurata K et al., Oncogene, revise). Intriguingly, we found that HDM2 not only relates to control of p53 protein amounts but also may regulate the kinetics of Noxa in NB cells. In HDM-2 over-expressed SK-N-SH cells, p53 downstream pathway was inactivated although p53 was accumulated. Although Noxa was accumulated in mitochondria before stimulation, Doxorubicin could not up-regulate Noxa in mitochondria and induce apoptosis in the HDM2-over-expressed SK-N-SH cells. These results indicate that HDM2 might be key molecule to control p53 stability and activities and to regulate Noxa kinetics in mitochondria in NB cells. We would like to do further analysis of the mitochondria apoptosis related molecules to develop new therapies for unfavorable neuroblastoma. Less
神经母细胞瘤(NB)是最常见的小儿交感神经系统实体恶性肿瘤。我们研究了NB细胞中p53依赖性细胞死亡的抑制剂。p53-E3泛素连接酶HDM 2在多柔比星耐药NB细胞中高表达,并与p53在细胞核中结合。值得注意的是,尽管HDM 2以蛋白酶体依赖的方式促进p53降解,但p53和HDM 2在多柔比星耐药NB细胞中均聚集。最近,已经报道了由天然存在的SNP 309引起的Mdm 2的过度产生抑制染色质结合的p53激活其靶基因的转录(JBC,Arva NC et al.,2005年)。这些结果促使我们研究SNP 309 HDM 2在NB细胞中的存在。然而,我们只能在SK-N-SH(敏感)细胞中检测到杂合SNP,而在IMR 32(耐药)、NB-19(耐药)和NB-9(敏感)细胞中检测不到杂合SNP。接下来,我们对HDM 2的p53结合结构域进行了测序, ...更多信息 为了验证p53-HDM 2在NB细胞中的相互作用,未发现HDM 2的p53结合结构域的突变,我们使用一组细胞系来确定神经母细胞瘤(NB)细胞中p53依赖的细胞死亡是否由凋亡细胞功能引起,并进一步研究通过p53依赖的途径诱导凋亡的分子机制。我们获得的证据表明,一种类型的p53依赖性应激,阿霉素(Doxo)管理,导致积累的p53在NB细胞的细胞核和磷酸化的几个丝氨酸残基在Doxo敏感和耐药细胞系。仅在Doxo敏感的NB细胞中观察到细胞中p53下游分子的上调和线粒体组分中Noxa的积累。通过Noxa敲低实验证实了Noxa在Doxo诱导的NB细胞死亡中的意义。发生线粒体功能障碍,包括细胞色素c释放和膜电位失调,并导致内源性半胱天冬酶途径的激活(Kurata K等人,Oncogene,revision).有趣的是,我们发现HDM 2不仅与p53蛋白量的控制有关,而且还可以调节NB细胞中Noxa的动力学。在HDM-2过表达的SK-N-SH细胞中,尽管p53积累,但p53下游通路被失活。虽然在刺激前Noxa在线粒体中积累,但阿霉素不能上调线粒体中的Noxa并诱导HDM 2过表达的SK-N-SH细胞凋亡。这些结果表明,HDM 2可能是控制NB细胞中p53稳定性和活性以及调节线粒体中Noxa动力学的关键分子。我们希望通过对线粒体凋亡相关分子的进一步研究,为神经母细胞瘤的治疗提供新的思路。少
项目成果
期刊论文数量(20)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Granulocyte-macrophage colony-stimulating factor induces de novo methylation of the p15 CpG island in hematopoietic cells
粒细胞-巨噬细胞集落刺激因子诱导造血细胞中 p15 CpG 岛从头甲基化
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Zhao XY;Sakashita K;Kamijo T;Hidaka E;Sugane;K;Kubota T;Koike K
- 通讯作者:Koike K
Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells
- DOI:10.1038/sj.onc.1210672
- 发表时间:2008-01-31
- 期刊:
- 影响因子:8
- 作者:Kurata, K.;Yanagisawa, R.;Kamijo, T.
- 通讯作者:Kamijo, T.
DFF45/ICAD restores cisplatin-induced unclear fragmentation but not DNA cleavage in DFF45-deficient neuroblastoma cells.
DFF45/ICAD 在 DFF45 缺陷的神经母细胞瘤细胞中恢复顺铂诱导的不清楚的片段化,但不能恢复 DNA 裂解。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Takahashi M;Kamijo T
- 通讯作者:Kamijo T
Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell lime
神经母细胞瘤细胞 Lime 中纯合缺失产生的新 p53 突变体的功能表征
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Nakamura Y;Kamijo T 他
- 通讯作者:Kamijo T 他
新しい小児慢性特定疾患治療研究事業に基く小児慢性疾患診療マニュアル
基于新的儿科特异性慢性病治疗研究项目的小儿慢性病治疗手册
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Yasutomi M;et al.;監修 加藤忠明
- 通讯作者:監修 加藤忠明
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAMIJO Takehiko其他文献
KAMIJO Takehiko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAMIJO Takehiko', 18)}}的其他基金
Development of cancer stem cell-targeted therapy by study of tumor sphere formation mechanism using comprehensive and genetic approach
通过综合遗传学方法研究肿瘤球形成机制,开发癌症干细胞靶向治疗
- 批准号:
24390269 - 财政年份:2012
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Screening of polycomb Bmi1 targets for development of Cancer Stem Cell-targeted therapy for neuroblastoma
筛选多梳 Bmi1 靶点以开发神经母细胞瘤的癌症干细胞靶向治疗
- 批准号:
21591377 - 财政年份:2009
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation of a new molecular target-based treatment of caneer-drug resistant pediatric solid tumors
癌症耐药儿童实体瘤新分子靶向治疗的研究
- 批准号:
15591098 - 财政年份:2003
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Molecular Mechanism of ARF-dependent apoptotic cell death
ARF依赖性细胞凋亡的分子机制分析
- 批准号:
13214040 - 财政年份:2001
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
Analysis of the mechanism for suppression of childhood leukemia via ARF-p53 pathway
ARF-p53通路抑制儿童白血病的机制分析
- 批准号:
12670736 - 财政年份:2000
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Development of combination immunotherapy using telomerase-targeted oncolytic virus against high-risk neuroblastoma
使用端粒酶靶向溶瘤病毒对抗高危神经母细胞瘤的联合免疫疗法的开发
- 批准号:
19K18054 - 财政年份:2019
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets
高危神经母细胞瘤的替代端粒维持机制作为预后指标和治疗靶点
- 批准号:
10225312 - 财政年份:2018
- 资助金额:
$ 2.11万 - 项目类别:
Study of ATRX mediated telomere maintenance in neuroblastoma by using genome editing technology (CRISPR/Cas9)
利用基因组编辑技术(CRISPR/Cas9)研究 ATRX 介导的神经母细胞瘤端粒维持
- 批准号:
18K15256 - 财政年份:2018
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets
高危神经母细胞瘤的替代端粒维持机制作为预后指标和治疗靶点
- 批准号:
10472494 - 财政年份:2018
- 资助金额:
$ 2.11万 - 项目类别:
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma
治疗耐药性神经母细胞瘤中 p53 和 Aurora A 的阻断
- 批准号:
8496155 - 财政年份:2012
- 资助金额:
$ 2.11万 - 项目类别:
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma
治疗耐药性神经母细胞瘤中 p53 和 Aurora A 的阻断
- 批准号:
8353311 - 财政年份:2012
- 资助金额:
$ 2.11万 - 项目类别:
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma
治疗耐药性神经母细胞瘤中 p53 和 Aurora A 的阻断
- 批准号:
8706995 - 财政年份:2012
- 资助金额:
$ 2.11万 - 项目类别:
DUSP26: A Novel Therapeutic Target in Neuroblastoma
DUSP26:神经母细胞瘤的新治疗靶点
- 批准号:
8423394 - 财政年份:2011
- 资助金额:
$ 2.11万 - 项目类别:
DUSP26: A Novel Therapeutic Target in Neuroblastoma
DUSP26:神经母细胞瘤的新治疗靶点
- 批准号:
8227975 - 财政年份:2011
- 资助金额:
$ 2.11万 - 项目类别:
DUSP26: A Novel Therapeutic Target in Neuroblastoma
DUSP26:神经母细胞瘤的新治疗靶点
- 批准号:
8625345 - 财政年份:2011
- 资助金额:
$ 2.11万 - 项目类别: